NGM Biopharmaceuticals, Inc.

333 Oyster Point Boulevard
South San Francisco
California
94080
United States

Tel: 650-243-5555

About NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc. is a private biotech company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to form a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine. To date, NGM Bio has generated a pipeline of six drug candidates in various stages of development, including NGM282 that recently demonstrated proof-of-concept in a Phase 2 study in non-alcoholic steatohepatitis (NASH). We have many more in preclinical development. In 2015, we entered into a broad, strategic collaboration with Merck that will provide us with the resources and flexibility to pursue our ambitious R&D goals and further extend our pipeline of novel drug candidates.

58 articles with NGM Biopharmaceuticals, Inc.

NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4

10/19/2020

ILT2 and ILT4, key myeloid and lymphoid checkpoints, may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistance
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

8/29/2020

The 24-week Phase 2 study met its primary endpoint, achieving a statistically significant reduction in liver fat content (LFC), and robust fibrosis improvement and resolution of NASH, with a favorable safety profile
NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020

8/18/2020

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitis (NASH) will be featured in an oral plenary presentation at The Digital International Liver Congress (ILC) 2020, which will be held virtual
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results

8/12/2020

--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-alcoholic steatohepatitis (NASH) with ongoing Phase 2b ALPINE 2/3 and ALPINE 4 clinical studies-- --Initiated Phase 2 CATALINA study of NGM621, a complement C3 inhibitory antibody to treat patients with geographic atrophy (GA)-- --$312.1 million in cash, cash equivalents and marketable
NGM Bio to Present at Two Upcoming Investor Conferences - July 31, 2020

7/31/2020

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

7/27/2020

-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a progressive, irreversible retinal degenerative disease with no approved therapies -- -- NGM621, a monoclonal antibody, is engineered to potently inhibit complement C3 with the treatment goal of reducing disease progression in patients with GA --
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.

6/8/2020

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the appointment of Carole Ho, M.D. to its Board of Directors. Dr. Ho currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics. “Carole’s background as a physician-scientist with deep industry expertise is ideally suited to NGM’s cu
NGM Bio to Present at Two Upcoming Investor Conferences

5/29/2020

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.
NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer

5/27/2020

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced the appointment of Siobhan Nolan Mangini as Chief Financial Officer (CFO).
NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results

5/13/2020

Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis)
NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

5/8/2020

NGM Biopharmaceuticals, Inc. announced that, due to public health and safety concerns related to the coronavirus pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders as a virtual-only meeting that will be held via live audio webcast.
NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

3/17/2020

NGM Biopharmaceuticals, Inc. (NGM or the Company) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today reported financial results for the fourth quarter and year ended December 31, 2019 and business highlights.
Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company

3/9/2020

NGM Biopharmaceuticals, Inc. announced that, effective March 13, 2020, Aetna Wun Trombley, Ph.D. will step down as President and Chief Operating Officer of the company to assume the role of Chief Executive Officer at an undisclosed privately held company.
NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference

2/25/2020

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and a business update at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, at 2:10 p.m. ET.
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients

2/24/2020

Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo
NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH

2/23/2020

NGM Biopharmaceuticals, Inc. will host a conference call and live webcast on Monday, February 24, 2020 at 8:30 a.m.
Clinical Catch-Up: February 10-14

2/17/2020

It was a very busy week for clinical trial news. Here’s a look.
NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)

2/11/2020

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), today announced the initiation of a Phase 1a/1b clinical study of NGM120, a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling, for the potential treatment of cancer and cancer anorexia/cachexia syndrome (CACS)
NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

12/5/2019

NGM Biopharmaceuticals, Inc. announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer of Invitae Corporation.
NGM Bio to Present at the Stifel 2019 Healthcare Conference

11/14/2019

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York, NY on Tuesday, November 19, 2019 at 3:00 p.m. ET.